Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Parkinson Disease 1Neuroendocrine Tumors 1Neuroblastoma 1Lewy Body Disease 1Congenital Hyperinsulinism 1Brain Neoplasms 1

Interventions

Radiosurgery 51Magnetic Resonance Spectroscopy 34Temozolomide 28Bevacizumab 24pembrolizumab 23Radiotherapy 20Nivolumab 20Specimen Handling 14Ipilimumab 13Cyclophosphamide 13Mental Status and Dementia Tests 12Carboplatin 12abemaciclib 10Radiation 10Blood Specimen Collection 9trastuzumab deruxtecan 8Proton Therapy 7Pemetrexed 7Memantine 7fluciclovine F-18 6binimetinib 6Paclitaxel 6Lomustine 6Etoposide 6Cisplatin 6Capecitabine 6encorafenib 5Trastuzumab 5Surveys and Questionnaires 5Surgical Procedures, Operative 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × 4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid × 1 year × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡